S&P 500   3,370.39 (-0.09%)
DOW   27,822.88 (-0.26%)
AAPL   455.18 (-1.06%)
CGC   17.11 (-1.21%)
BABA   256.20 (+0.98%)
TSLA   1,645.23 (+1.49%)
GE   6.58 (-0.30%)
F   7.01 (-0.28%)
DIS   130.00 (-0.73%)
BA   173.60 (-0.65%)
S&P 500   3,370.39 (-0.09%)
DOW   27,822.88 (-0.26%)
AAPL   455.18 (-1.06%)
CGC   17.11 (-1.21%)
BABA   256.20 (+0.98%)
TSLA   1,645.23 (+1.49%)
GE   6.58 (-0.30%)
F   7.01 (-0.28%)
DIS   130.00 (-0.73%)
BA   173.60 (-0.65%)
S&P 500   3,370.39 (-0.09%)
DOW   27,822.88 (-0.26%)
AAPL   455.18 (-1.06%)
CGC   17.11 (-1.21%)
BABA   256.20 (+0.98%)
TSLA   1,645.23 (+1.49%)
GE   6.58 (-0.30%)
F   7.01 (-0.28%)
DIS   130.00 (-0.73%)
BA   173.60 (-0.65%)
S&P 500   3,370.39 (-0.09%)
DOW   27,822.88 (-0.26%)
AAPL   455.18 (-1.06%)
CGC   17.11 (-1.21%)
BABA   256.20 (+0.98%)
TSLA   1,645.23 (+1.49%)
GE   6.58 (-0.30%)
F   7.01 (-0.28%)
DIS   130.00 (-0.73%)
BA   173.60 (-0.65%)
Log in

NASDAQ:FOLDAmicus Therapeutics Stock Price, Forecast & News

$14.62
+0.03 (+0.21 %)
(As of 08/14/2020 10:31 AM ET)
Add
Compare
Today's Range
$14.30
Now: $14.62
$14.71
50-Day Range
$14.45
MA: $15.16
$15.89
52-Week Range
$6.25
Now: $14.62
$16.13
Volume2.40 million shs
Average Volume3.19 million shs
Market Capitalization$3.78 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.28
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease. The company has a strategic alliance with GlaxoSmithKline plc to develop and commercialize Galafold as a monotherapy and in combination with ERT for Fabry disease, as well as a research and development collaboration with the University of Pennsylvania to develop AAV gene therapies. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Read More
Amicus Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:FOLD
CUSIP03152W10
Phone609-662-2000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$182.24 million
Book Value$1.87 per share

Profitability

Net Income$-356,390,000.00
Net Margins-155.73%

Miscellaneous

Employees508
Market Cap$3.78 billion
Next Earnings Date11/9/2020 (Estimated)
OptionableOptionable
$14.62
+0.03 (+0.21 %)
(As of 08/14/2020 10:31 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

How has Amicus Therapeutics' stock price been impacted by Coronavirus?

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FOLD shares have increased by 81.6% and is now trading at $14.62.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Amicus Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Amicus Therapeutics
.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020.
View our earnings forecast for Amicus Therapeutics
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) issued its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.06. The biopharmaceutical company earned $62.35 million during the quarter, compared to the consensus estimate of $62.66 million. Amicus Therapeutics had a negative net margin of 155.73% and a negative return on equity of 63.24%.
View Amicus Therapeutics' earnings history
.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics issued an update on its FY 2020 Pre-Market earnings guidance on Monday, August, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $250-260 million, compared to the consensus revenue estimate of $254.82 million.

What price target have analysts set for FOLD?

9 Wall Street analysts have issued 12 month price targets for Amicus Therapeutics' shares. Their forecasts range from $12.50 to $31.00. On average, they expect Amicus Therapeutics' share price to reach $20.28 in the next twelve months. This suggests a possible upside of 38.7% from the stock's current price.
View analysts' price targets for Amicus Therapeutics
.

Has Amicus Therapeutics been receiving favorable news coverage?

Media headlines about FOLD stock have been trending positive on Friday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Amicus Therapeutics earned a coverage optimism score of 2.7 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future.
View the latest news about Amicus Therapeutics
.

Who are some of Amicus Therapeutics' key competitors?

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Sangamo Therapeutics (SGMO), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD) and Cara Therapeutics (CARA).

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the following people:
  • Mr. John F. Crowley, Chairman & CEO (Age 52)
  • Mr. Bradley L. Campbell, Pres, COO & Director (Age 43)
  • Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 56)
  • Dr. Jay A. Barth, Chief Medical Officer (Age 55)
  • Ms. Daphne E. Quimi, Chief Financial Officer (Age 53)

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (3.08%), Jennison Associates LLC (1.97%), Victory Capital Management Inc. (1.36%), Goldman Sachs Group Inc. (1.04%), Bank of New York Mellon Corp (0.88%) and Assenagon Asset Management S.A. (0.61%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Life Sciences Maste Perceptive, Margaret G Mcglynn, Michael Raab, Perceptive Advisors Llc, Samantha Prout and William D Baird III.
View institutional ownership trends for Amicus Therapeutics
.

Which institutional investors are selling Amicus Therapeutics stock?

FOLD stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Phoenix Holdings Ltd., Victory Capital Management Inc., Peregrine Capital Management LLC, Candriam Luxembourg S.C.A., FMR LLC, GW&K Investment Management LLC, and Asymmetry Capital Management L.P.. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Jay Barth, John F Crowley, Margaret G Mcglynn, Michael Raab, and Samantha Prout.
View insider buying and selling activity for Amicus Therapeutics
.

Which institutional investors are buying Amicus Therapeutics stock?

FOLD stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., SG Americas Securities LLC, Essex Investment Management Co. LLC, Silvercrest Asset Management Group LLC, Fairmount Funds Management LLC, Federated Hermes Inc., Affinity Wealth Management LLC, and Athanor Capital LP. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for Amicus Therapeutics
.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $14.62.

How big of a company is Amicus Therapeutics?

Amicus Therapeutics has a market capitalization of $3.78 billion and generates $182.24 million in revenue each year. The biopharmaceutical company earns $-356,390,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. Amicus Therapeutics employs 508 workers across the globe.

What is Amicus Therapeutics' official website?

The official website for Amicus Therapeutics is www.amicusrx.com.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.